NeuroMetrix (NSDQ:NURO) landed FDA clearance for its Sensus pain management system, a non-invasive transcutaneous electrical nerve stimulator designed to relieve the symptoms of diabetic neuropathy.
Neurometrix
iCad soars on Medicare reimbursement nod | Wall Street Beat
NeuroMetrix slides on 3Q results
NeuroMetrix (NSDQ:NURO) reported another consecutive quarter at a net loss, spurring a 9.1% drop on Wall Street yesterday, where shares closed at 50¢.
Diabetes: Glooko links up with Wal-Mart | Wall Street Beat
Diabetes: NeuroMetrix jumps on FDA nod for pain management system
Shares of NeuroMetrix (NSDQ:NURO) are soaring this morning on news of a U.S. regulatory win for its Sensus pain management system.
The FDA granted 510(k) clearance to the system but has yet to formally announce the decision, according to the watchdog agency’s website.
NURO shares surged as much as 22% this morning on the news and were up 10.8% to 72¢ as of about 10:20 a.m.
Diabetes: Medtronic’s Resolute stent performs well in non-diabetics, too | Wall Street Beat
Smokers in China tip the scale in med-tech’s favor | Wall Street Beat
The Chinese medical device market may triple by 2018, partially due to high rates of tobacco consumption and a rapidly growing economy, according to a market report.
Zimmer slides on Q1 results | Earnings Roundup
Diabetes: NeuroMetrix touts weight loss study at Joslin Diabetes Center | MassDevice.com On Call
MASSDEVICE ON CALL — Waltham, Mass.-based NeuroMetrix (NSDQ:NURO) announced its support of the Joslin Diabetes Center’s "Why Wait" program targeting obese patients with diabetes.
Abbott wins FDA nod for next-gen cataract laser | Regulatory Roundup
Boston Scientific launches Pluromed’s BackStop kidney stone treatment | Wall Street Beat
Boston Scientific (NYSE:BSX) launched its BackStop kidney stone treatment product in the U.S. and certain international markets this week.